BB Biotech AG - Asset Resilience Ratio
BB Biotech AG (BION) has an Asset Resilience Ratio of 99.99% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BB Biotech AG (BION) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how BB Biotech AG's Asset Resilience Ratio has changed over time. See BB Biotech AG (BION) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down BB Biotech AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BION market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF2.16 Million | 0.12% |
| Short-term Investments | CHF1.84 Billion | 99.87% |
| Total Liquid Assets | CHF1.84 Billion | 99.99% |
Asset Resilience Insights
- Very High Liquidity: BB Biotech AG maintains exceptional liquid asset reserves at 99.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BB Biotech AG Industry Peers by Asset Resilience Ratio
Compare BB Biotech AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for BB Biotech AG (2012–2024)
The table below shows the annual Asset Resilience Ratio data for BB Biotech AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 100.00% | CHF2.41 Billion ≈ $3.04 Billion |
CHF2.41 Billion ≈ $3.04 Billion |
+0.07pp |
| 2023-12-31 | 99.93% | CHF2.64 Billion ≈ $3.33 Billion |
CHF2.64 Billion ≈ $3.33 Billion |
+0.46pp |
| 2022-12-31 | 99.47% | CHF3.04 Billion ≈ $3.84 Billion |
CHF3.05 Billion ≈ $3.86 Billion |
-0.47pp |
| 2021-12-31 | 99.94% | CHF3.64 Billion ≈ $4.60 Billion |
CHF3.64 Billion ≈ $4.61 Billion |
+0.03pp |
| 2020-12-31 | 99.90% | CHF3.96 Billion ≈ $5.01 Billion |
CHF3.96 Billion ≈ $5.01 Billion |
+0.04pp |
| 2019-12-31 | 99.86% | CHF3.55 Billion ≈ $4.49 Billion |
CHF3.55 Billion ≈ $4.49 Billion |
-0.11pp |
| 2018-12-31 | 99.97% | CHF3.09 Billion ≈ $3.90 Billion |
CHF3.09 Billion ≈ $3.90 Billion |
+0.06pp |
| 2017-12-31 | 99.91% | CHF3.63 Billion ≈ $4.60 Billion |
CHF3.64 Billion ≈ $4.60 Billion |
+0.37pp |
| 2016-12-31 | 99.54% | CHF3.21 Billion ≈ $4.06 Billion |
CHF3.23 Billion ≈ $4.08 Billion |
+0.36pp |
| 2015-12-31 | 99.18% | CHF4.11 Billion ≈ $5.20 Billion |
CHF4.14 Billion ≈ $5.24 Billion |
-0.43pp |
| 2014-12-31 | 99.62% | CHF3.52 Billion ≈ $4.45 Billion |
CHF3.53 Billion ≈ $4.47 Billion |
+1.64pp |
| 2013-12-31 | 97.98% | CHF2.17 Billion ≈ $2.74 Billion |
CHF2.21 Billion ≈ $2.80 Billion |
+0.18pp |
| 2012-12-31 | 97.80% | CHF1.34 Billion ≈ $1.70 Billion |
CHF1.37 Billion ≈ $1.74 Billion |
-- |
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more